Stock Price Quote

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE585.45-10.45 (-1.75 %)
PREV CLOSE ( ) 595.90
OPEN PRICE ( ) 574.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5474
TODAY'S LOW / HIGH ( )574.30 599.15
52 WK LOW / HIGH ( )500 975
NSE585.95-11.45 (-1.92 %)
PREV CLOSE( ) 597.40
OPEN PRICE ( ) 590.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 585.95 (26)
VOLUME 101557
TODAY'S LOW / HIGH( ) 567.05 599.90
52 WK LOW / HIGH ( )499 979.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 20-01 1995
Management Info
Kishor M Shah - Chairman Mahendra G Patel - Managing Director
Registered Office

Address Lincoln House", Behind Satyam Complex,Science City Road,Sola,
Ahmedabad,
Gujarat-380060

Phone 079-41078000

Email info@lincolnpharma.com

Website www.lincolnpharma.com

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

15May Lincoln Pharmaceuticals informs about
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..
15May Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that Meeting of the Board of Direct..
09May Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that the Company does not fall unde..
05Apr Lincoln Pharmaceuticals informs about
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and..
05Feb Lincoln Pharmaceuticals informs about
Lincoln Pharmaceuticals has informed that the meeting of the Board of Di..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit115.74823.469999999999
Gross Profit 162.46 1091.89
Operating Profit 198.391239.71
Net Sales 1681.836232.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  10524.65 (3.40%)
M.Cap ( in Cr)26311.63
RPG Life Sciences (BSE)
peergroup  2339.50 (4.07%)
M.Cap ( in Cr)3869.30
Abbott India (BSE)
peergroup  31545.15 (0.22%)
M.Cap ( in Cr)67031.24
Concord Biotech (BSE)
peergroup  2110.55 (2.44%)
M.Cap ( in Cr)22079.77
Onesource Specialty (BSE)
peergroup  2024.35 (2.45%)
M.Cap ( in Cr)23171.93

Shareholding Pattern

PROMOTERS 49.78%
NON-INSTITUTION 45.22%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Lincoln Pharmaceuticals Ltd.

Lincoln Pharmaceuticals Ltd. was incorporated in the year 1995. Its today's share price is 585.45. Its current market capitalisation stands at Rs 1172.64 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6030.22 Cr and Total Income of Rs.6149.72 Cr. The company's management includes Trusha Shah, Saurin J Parikh, Nareshkumar Suthar, Seema Mehta, Rajnikant G Patel, Ashish Patel, Munjal M Patel, Hashmukhbhai Patel, Mahendra G Patel, Kishor M Shah.

It is listed on the BSE with a BSE Code of 531633 , NSE with an NSE Symbol of LINCOLN and ISIN of INE405C01035. It's Registered office is at Lincoln House", Behind Satyam Complex,Science City Road,SolaAhmedabad-380060, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Chandulal M Shah & Co, DK Chhajer & Co, JT Shah & Co, Samir M Shah & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.